Literature DB >> 10992004

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

H M Sarau1, D E Griswold, B Bush, W Potts, P Sandhu, D Lundberg, J J Foley, D B Schmidt, E F Webb, L D Martin, J J Legos, R G Whitmore, F C Barone, A D Medhurst, M A Luttmann, G A Giardina, D W Hay.   

Abstract

The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car boxami de], a human NK-3 receptor (hNK-3R) antagonist, was determined. SB-222200 inhibited (125)I-[MePhe(7)]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K(i) = 4.4 nM and antagonized NKB-induced Ca(2+) mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC(50) = 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of (125)I-[MePhe(7)]NKB (K(i) = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC(50) = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED(50) values of approximately 5 mg/kg. SB-222200 effectively crossed the blood-brain barrier in the mouse and rat. The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concentrations of the compound. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (C(max) = about 400 ng/ml) and bioavailability of 46%. The preclinical profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors, in particular in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992004

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Evidence from the agonadal juvenile male rhesus monkey (Macaca mulatta) for the view that the action of neurokinin B to trigger gonadotropin-releasing hormone release is upstream from the kisspeptin receptor.

Authors:  Suresh Ramaswamy; Stephanie B Seminara; Tony M Plant
Journal:  Neuroendocrinology       Date:  2011-08-10       Impact factor: 4.914

2.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen.

Authors:  Nicolas André; Nadia Cherouati; Cécile Prual; Tania Steffan; Gabrielle Zeder-Lutz; Thierry Magnin; Franc Pattus; Hartmut Michel; Renaud Wagner; Christoph Reinhart
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

4.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

5.  Pharmacological characterization of tachykinin tetrabranched derivatives.

Authors:  Chiara Ruzza; Anna Rizzi; Davide Malfacini; Maria Camilla Cerlesi; Federica Ferrari; Erika Marzola; Caterina Ambrosio; Cristina Gro; Salvadori Severo; Tommaso Costa; Girolamo Calo; Remo Guerrini
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

6.  A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.

Authors:  Karuppiah Chockalingam; Rudo L Simeon; Charles M Rice; Zhilei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

7.  Increased neurokinin B (Tac2) expression in the mouse arcuate nucleus is an early marker of pubertal onset with differential sensitivity to sex steroid-negative feedback than Kiss1.

Authors:  John C Gill; Víctor M Navarro; Cecilia Kwong; Sekoni D Noel; Cecilia Martin; Shuyun Xu; Donald K Clifton; Rona S Carroll; Robert A Steiner; Ursula B Kaiser
Journal:  Endocrinology       Date:  2012-08-14       Impact factor: 4.736

8.  Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms.

Authors:  Andrew D Grant; Roksana Akhtar; Norma P Gerard; Susan D Brain
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

9.  Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.

Authors:  Frank Cloutier; Brice Ongali; Kathleen Deschamps; Jonathan Brouillette; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 10.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.